We're #hiring a new Clinical Trial Associate in Malvern, Pennsylvania. Apply today or share this post with your network.
Ocugen
Biotechnology Research
Malvern, Pennsylvania 13,315 followers
Approaching healthcare innovation with purpose and agility to deliver new breakthroughs for people facing disease.
About us
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
- Website
-
https://www.ocugen.com
External link for Ocugen
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Malvern, Pennsylvania
- Type
- Public Company
- Founded
- 2013
- Specialties
- ophthalmology, biopharmaceutical, biotechnology, therapeutics biologics, rare diseases, inherited retinal disorders, and wet AMD
Locations
-
Primary
263 Great Valley Pkwy
Malvern, Pennsylvania 19355, US
Employees at Ocugen
-
Umair Qazi
Associate Director, Clinical Operations
-
Kevin Smith
Manager Cell & Gene Therapy Manufacturing
-
Tiffany Hamilton
Results-oriented communications leader and brand strategist
-
Anil K. Rattan, Ph.D.
Expert in building & maintaining phase-appropriate GxP QMS framework from scratch using industry best practices, regulatory compliance & adherence to…
Updates
-
Thank you CGTLive for highlighting the science behind our modifier gene therapy platform and the ongoing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa in your interview with Ocugen CSO, Arun Upadhyay #IRD #RP #CourageousInnovation
“Our approach is more gene-agnostic in nature, which not only enhances the function of the photoreceptor, but also helps with preserving the surviving retinal cells through cellular and molecular homeostasis.” #genetherapy #Ophthalmology Ocugen Watch: https://lnkd.in/g7xMBhmK
-
We're #hiring a new Medical Monitor in Malvern, Pennsylvania. Apply today or share this post with your network.
-
Dr. Arun Upadhyay, Ocugen’s Chief Scientific Officer, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference in New York, NY. You can participate virtually via webcast: https://lnkd.in/ezFv959g Read the full press release here: https://bit.ly/3Bjjqv9 #ModifierGeneTherapy #GeneticMedicines #ChardanGMConf
-
Last week, Ocugen’s Chief Scientific Officer, Dr. Arun Upadhyay, presented an e poster at the 24th Annual Euretina Congress in Barcelona, Spain. The team also spent time engaging retina thought leaders from across the globe and joined in the celebration of World Retina Day on September 21. #RetinaCare #Ophthalmology #EURETINA24
-
Thank you Chardan and Daniil Gataulin, Ph.D. for once again including Ocugen in this informative series. #ModifierGeneTherapy #GA
Chardan biotech analyst, Daniil Gataulin, PhD hosted the 2nd annual Virtual Ophthalmology Summit focusing on AMD and Diabetes Related Ocular Disease. Participating companies included: Adverum Biotechnologies, Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Ocugen, Oculis, Outlook Therapeutics, Inc., REGENXBIO Inc., UNITY Biotechnology. View session replays here: https://lnkd.in/es4yjHrq or to read the published takeaways, please reach out to [email protected]. #ChardanResearch #Ophthalmology #biotech
-
This week, Dr. Shankar Musunuri, Chairman, CEO & Co-founder of Ocugen sat down with Dr. Swayampakula Ramakanth, Managing Director, Equity Research at H.C. Wainwright & Co., LLC for a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. During the session, Dr. Musunuri provided insights into recent milestones for the Phase 3 OCU400 liMeliGhT clinical trial and anticipated milestones for the OCU410 ArMaDa clinical trial, now in Phase 2. It was great to both make introductions and continue the conversation with investors at this important conference. #HCWainwrightGlobal
-
Dr. Shankar Musunuri will participate in the panel: "Persistent Challenges: Right-Sizing Regulations and Setting Standards Beyond the Biomedical Sphere." The primary goal of this workshop series is to identify short-, medium-, and long-term opportunities for U.S.- India biotechnology cooperation consistent with the initiative on Critical and Emerging Technology (iCET) and beyond. #collaboration #access
-
Thank you, Investing News Network, for recognizing Ocugen as a longevity and anti-aging stock to watch: https://lnkd.in/e9NbA_XV #genetherapy #celltherapy #courageousinnovation
5 US Longevity and Anti-aging Stocks to Watch in 2024
investingnews.com
-
Ocugen’s CSO, Head of Research & Development, Dr. Arun Upadhyay, will be among the featured speakers at the 5th Annual Gene Therapy for Ophthalmic Disorders Summit in Boston, Mass. from September 10-12, 2024. Dr. Upadhyay will present “Advancements in Gene Therapy for Ophthalmic Disorders: Ocugen’s Clinical Program Updates” at 11:30 a.m. on Thursday, September 12.